Skip to main content
Evotec to lead Sanofi's infectious disease pipeline development

Sanofi has turned over to Evotec its infectious disease pipeline, which consists of more than 10 undisclosed early-stage preclinical assets. Under the terms of the deal, Evotec will get $73.9 million upfront and will lead the research and development on the portfolio while Sanofi will retain undisclosed advancement, manufacturing and marketing option rights to the assets it contributes.

Full Story: